kidney semaglutide Long-term outcomes of in obesity and cardiovascular disease in the SELECT trial AHA 2024: semaglutide continues to
Description
The study participants were also provided with a questionnaire-based assessment of treatment satisfaction
Samaniego 1 , R
More than half (54%) of those who take GLP-1s for weight loss spend less than a year on the medication, while just 18% stay on them for more than two years, according to a Sermo physician survey
Digbi Healths GLP-1 Program is a comprehensive, employer-backed telemedicine solutionnow expanded with a self-pay optionthat streamlines every step of the GLP-1 journey for employees and their eligible family members, from clinical evaluation to prescription to fulfillment
